Development of a Pharmacokinetic/Pharmacodynamic Model for Carvedilol to Predict β1-Blockade in Patients with Congestive Heart Failure

American Journal of Cardiology

Volumn 98, Issue 7 SUPPL., 2006, Pages 27-31

  Tenero, David M ^a   Henderson, Linda S ^a   Campanile, Andrea M ^a   Baidoo, Charlotte A ^a   Boyle, Duane ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; CARVEDILOL;

AREA UNDER THE CURVE; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; CARDIAC PATIENT; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONGESTIVE HEART FAILURE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFECT; DRUG FORMULATION; EXERCISE; HEART INFARCTION; HEART LEFT VENTRICLE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MODEL; PHARMACODYNAMICS; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; RECEPTOR BLOCKING;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; AREA UNDER CURVE; CARBAZOLES; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; MODELS, STATISTICAL; PROPANOLAMINES; SEVERITY OF ILLNESS INDEX;

EID: 33749121571     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.07.016     Document Type: Article

References (10)

1. Abrahamsson B., Lucker P., Olofsson B., Regardh C.G., Sandberg A., Wieselgren I., and Bergstrand R. The relationship between metoprolol plasma concentration and beta 1-blockade in healthy subjects: a study on conventional metoprolol and metoprolol CR/ZOK formulations. J Clin Pharmacol 30 suppl 2 (1990) S46-S54
2. Luzier A.B., Killian A., Wilton J.H., Wilson M.F., Forrest A., and Kazierad D.J. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 66 (1999) 594-601
3. Lalonde R.L., Straka R.J., Pieper J.A., Bottorff M.B., and Mirvis D.M. Propranolol pharmacodynamic modeling using unbound and total concentrations in healthy volunteers. J Pharmacokinet Biopharm 15 (1987) 569-582
4. Lalonde R.L., Tenero D.M., Bottorff M.B., Given B.D., Kramer W.G., and Affrime M.B. Pharmacodynamic modeling of the cardiovascular effects of dilevalol. [abstract]. Clin Pharmacol Ther 45 (1989) 179
5. de Mey C., Breithaupt K., Schloos J., Neugebauer G., Palm D., and Belz G.G. Dose-effect and pharmacokinetic-pharmacodynamic relationships of the beta 1-adrenergic receptor blocking properties of various doses of carvedilol in healthy humans. Clin Pharmacol Ther 55 (1994) 329-337
6. Data on file (2006), GlaxoSmithKline, Research Triangle Park, NC
7. Efron B., and Tibshirani R.J. Bootstrap methods for standard errors, confidence intervals and other measures of statistical accuracy. Stat Sci 1 (1986) 54-75
8. Montgomery D.C., Peck E.A., and Vining G.G. Introduction to Linear Regression Analysis. 3rd ed. (2001), John Wiley, Hoboken, NJ 301-302
9. Packer M., Lukas M.A., Tenero D.M., Baidoo C.A., Greenberg B.H., and 369 Study Group. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction. Am J Cardiol 98 suppl (2006) 39L-45L
10. Chow S.C., and Liu J.P. Design and Analysis of Bioavailability and Bioequivalence Studies (2000), Marcel Dekker, New York 83